Group 1 - Chengda Pharmaceutical announced that on January 14, 2026, it will accept an investor survey conducted by Cinda Securities, with participation from the company's director and general manager, Lu Gang, who will address investor inquiries [1] Group 2 - Haili Biological's acquisition of a company has seen a ninefold increase in value, yet the valuation has halved over the past eight months, raising concerns as its largest client is a company that has not yet been established [1]

Group 1: Small Nucleic Acid Business - The company's small nucleic acid business primarily includes phosphoramidite monomers and GalNAc delivery systems, with the capability to provide modified monomer processes to meet diverse customer needs [2][3] - Pricing for small nucleic acid monomers varies based on customer requirements, including different segments, quantities, and stages [3] - The company began its small nucleic acid business layout in 2024, driven by overseas agency promotion and technical cooperation [3] Group 2: Supply Chain and Production Capacity - MNC suppliers generally do not change key material suppliers easily due to the need for global registration and product process validation [3] - The company's production capacity is expected to meet the demands of small nucleic acid business as fundraising projects gradually release capacity [3] Group 3: Stem Cell Projects - The company has made progress in its cell therapy projects, including the completion of GMP facility design, installation, and validation for heart and brain infarction projects [3] - Technical transfers for umbilical cord mesenchymal stem cells have been completed, establishing seed, master, and working cell banks, along with method development and validation for analysis [3] Group 4: Investor Relations Activity - The investor relations activity took place on January 14, 2026, from 10:30 to 11:30 in the company meeting room, involving various investment firms [2] - The activity did not involve the disclosure of any undisclosed significant information [3]

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].

Core Viewpoint - The innovative drug sector experienced a significant rally, with notable stock price increases among various companies [1] Group 1: Company Performance - Weikang Pharmaceutical saw its stock price rise by over 18% [1] - Qianfang Bio and Shanghai Yizhong both increased by more than 10% [1] - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical also experienced upward movement in their stock prices [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical announced the approval of a proposal to use part of the raised funds to permanently supplement its working capital during the first extraordinary general meeting of shareholders in 2026 [2] Group 2 - The announcement was made on January 6, indicating the company's proactive approach to managing its financial resources [2]

北京中伦文德（杭州）律师事务所 关于 诚达药业股份有限公司 2026 年第一次临时股东会的 法律意见书 北京中伦文德（杭州）律师事务所 地址：杭州市萧山区钱江世纪城广孚中心 1301 电话：0571-83685215 传真：0571-83685215 邮编：311200 北京中伦文德（杭州）律师事务所 法律意见书 北京中伦文德（杭州）律师事务所 关于诚达药业股份有限公司 2026 年第一次临时股东会的 法律意见书 致：诚达药业股份有限公司 北京中伦文德（杭州）律师事务所（以下称"本所"）接受诚达药业股份有 限公司（以下称"公司"）的委托，指派律师出席公司 2026 年第一次临时股东 会（以下称"本次股东会"），本所律师根据《中华人民共和国公司法》（以下 称"《公司法》"）、《中华人民共和国证券法》（以下称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所上 市公司股东会网络投票实施细则》等法律、法规和规范性法律文件以及《诚达药 业股份有限公司章程》（以下称"《公司章程》"）的规定，就公司本次股东会 的召集召开程序、出席会议人员的资格、召集人的资格、表决程序和表决结果等 ...

证券代码：301201 证券简称：诚达药业 公告编号：2026-001 诚达药业股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2、召开地点：浙江省嘉兴市嘉善县惠民街道黄河路 36 号诚达药业股份有限 公司会议室。 特别提示： 1、本次股东会不存在否决议案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议时间：2026 年 1 月 6 日（星期二）下午 14：00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2026 年 1 月 6 日的交易时间，即 9:15-9:25、9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为：2026 年 1 月 6 日 9:15—15:00。 3、召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 4、召集人：董事会 5、主持人：董事长葛建利女士 6、本次会议的召集、召开符合《中华人民共和国公司法》、《上市公司股 东会规则》、《深圳证 ...

Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, closing at 40.70 yuan with a drop of 3.85%, indicating it is in a state of breaking below its initial public offering price [1] Group 1: IPO and Financials - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest price recorded on the first day of trading was 188.00 yuan, marking the peak since its listing [1] - The total funds raised from the IPO amounted to 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original target by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including pharmaceutical intermediates, raw materials, and R&D center expansion [1] Group 2: Shareholder Returns - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares held [2] - The record date for this equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2] Group 3: Management - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin holding Canadian permanent residency [2]

光大证券股份有限公司 培训地点：诚达药业会议室 培训对象：公司实际控制人以及部分董事、监事、高级管理人员 二、培训内容 本次现场培训前，光大证券制作了培训讲义，并提前向公司发出了关于本次 培训的通知。 本次培训主要对深交所于 2025 年修订发布的《上市公司自律监管指引第 2 号-创业板上市公司规范运作》进行了重点讲解。 关于诚达药业股份有限公司 2025 年度现场培训情况报告 光大证券股份有限公司（以下简称"光大证券"、"保荐机构"）作为诚达 药业股份有限公司（以下简称"诚达药业"、"公司"）首次公开发行股票并在 创业板上市的保荐机构，根据《深圳证券交易所上市公司自律监管指引第 13 号 ——保荐业务》等有关规定，于 2025 年 12 月 16 日对公司实际控制人以及部分 董事、监事、高级管理人员进行了现场培训，现将培训情况报告如下： 一、培训基本情况 培训时间：2025 年 12 月 16 日 （以下无正文） （此页无正文，为《光大证券股份有限公司关于诚达药业股份有限公司2025 年度现场培训情况报告》之签字盖章页） 保荐代表人： 杨科 韩剑龙 光大证券股份有限公司 2025 年 12 月 30 日 三 ...

光大证券股份有限公司关于 诚达药业股份有限公司 2025年度持续督导现场检查报告 | 保荐人名称：光大证券股份有限公司 被保荐公司简称：诚达药业 | | --- | | 保荐代表人姓名：杨科 联系电话：021-22169999 | | 保荐代表人姓名：韩剑龙 联系电话：021-22169999 | | 现场检查人员姓名：杨科、耿忠良 | | 现场检查对应期间：2025 年度 | | 现场检查时间：2025 年 12 月 16 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 查阅公司相关规章制度、三会文件、信息披露文件；访谈公司实际控制人、董事 | | 会秘书、财务总监等人员。 | | 1.公司章程和公司治理制度是否完备、合规 √ | | √ 2.公司章程和股东会、董事会规则是否得到有效执行 | | 3.股东会、董事会会议记录是否完整，时间、地点、出席 √ | | 人员及会议内容等要件是否齐备，会议资料是否保存完整 | | 4.股东会、董事会会议决议是否由出席会议的相关人员签 √ | | 名确认 | | 5.公司董事、高级管理人员是否按照有关法 ...